Article
Biochemistry & Molecular Biology
Bo Ahren
Summary: In this study, the contribution of GIP and GLP-1 to insulin response to oral glucose in female mice was investigated using receptor antagonists. It was found that both GIP and GLP-1 are required for a normal incretin effect in female mice, and no other incretin hormone is likely present in this species.
Review
Endocrinology & Metabolism
Qiming Tan, Seun E. Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Mueller, Andrea M. Haqq
Summary: GLP-1 has been extensively studied as a therapeutic target for obesity and type 2 diabetes. Improvement in the pharmacokinetic profile of GLP-1R agonists and the recent clinical success of GIPR agonists have opened up new possibilities for the treatment of obesity and diabetes.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, Andreas F. H. Pfeiffer
Summary: Incretin hormones GIP and GLP-1 play a significant role in insulin secretion and glucose tolerance in the gut-endocrine pancreas axis. They also have additional effects on bone remodelling, lipid storage, gastric emptying, and may provide benefits for cardiovascular complications and neurodegenerative disorders. Recent research on GIP/GLP-1 receptor co-agonists has renewed interest in the potential therapeutic applications of incretin hormones.
DIABETES OBESITY & METABOLISM
(2021)
Article
Endocrinology & Metabolism
Jonathan M. Wilson, Yanzhu Lin, M. Jane Luo, Gary Considine, Amy L. Cox, Lenden M. Bowsman, Deborah A. Robins, Axel Haupt, Kevin L. Duffin, Giacomo Ruotolo
Summary: In a phase 2 trial, tirzepatide reduced HbA1c and body weight dose-dependently in patients with type 2 diabetes, and also decreased several biomarkers associated with cardiovascular risk factors, showing potential positive effects on cardiovascular health.
DIABETES OBESITY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Melinda Danowitz, Diva D. De Leon
Summary: Incretin hormones, especially GLP-1, play an important role in the pathophysiology of hyperinsulinemic hypoglycemia. Understanding the mechanisms of incretin hormones is crucial for exploring GLP-1 receptor as a therapeutic target for these conditions.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Editorial Material
Biochemistry & Molecular Biology
Vincent Marks
Summary: The aim of this personal reminiscence is to introduce the seminal work carried out in the 1960s and 1970s that paved the way for the development of highly effective long-acting GLP-1R agonists and GLP1R/GIPR co-agonists, which are currently used in the clinical treatment of type 2 diabetes and obesity. The article highlights the contributions made by the author's collaborators Ellis Samols and Desmond Turner in understanding the nature and significance of gut glucagon-like immunoreactivity (enteroglucagon) and GIP. The identification of the potent incretin GLP-1(7-36)amide in the 1980s aligned with the earlier postulations by Samols and others in 1966 regarding the existence of a glucagon-like substance with incretin-like properties.
Article
Endocrinology & Metabolism
Arihiro Kiyosue, Julia P. Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J. Heine
Summary: The aim of this study was to evaluate the safety and efficacy of tirzepatide in East Asian individuals of different ages and body mass index (BMI). Data from clinical trials in East Asian countries were analyzed, and the results showed that tirzepatide had similar safety and efficacy profiles in East Asian participants, regardless of age and BMI.
DIABETES OBESITY & METABOLISM
(2023)
Article
Medicine, General & Internal
Masahiro Sato, Hiroki Fujita, Hiroki Yokoyama, Atsushi Mikada, Yohei Horikawa, Yuya Takahashi, Yuichiro Yamada, Hironori Waki, Takuma Narita
Summary: This study analyzed the relationships among postprandial plasma excursions of active glucagon-like peptide-1 (aGLP-1) and active gastric inhibitory polypeptide (aGIP), skeletal muscle mass, and body fat mass in type 2 diabetes patients treated with different medications. The results showed that the use of miglitol and sitagliptin did not affect skeletal muscle mass but decreased body fat mass, and the changes in aGIP were correlated with changes in body fat mass. Overall, this study suggests possible interrelationships among postprandial plasma aGIP excursion modified by sitagliptin, skeletal muscle mass, and body fat mass.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Julia Ast, Johannes Broichhagen, David J. Hodson
Summary: GLP1R and GIPR are important targets for diabetes and obesity treatment, but little is known about their localization and detection. The low abundance of GLP1R and GIPR, along with a lack of specific reagents, complicates the understanding of their mechanisms of action in target organs.
Article
Endocrinology & Metabolism
Pamela Bowman, Kashyap A. Patel, Timothy J. McDonald, Jens J. Holst, Bolette Hartmann, Maria Leveridge, Beverley M. Shields, Suzie Hammersley, Steve R. Spaull, Bridget A. Knight, Sarah E. Flanagan, Maggie H. Shepherd, Rob C. Andrews, Andrew T. Hattersley
Summary: This study aimed to assess the incretin hormone response to carbohydrate and protein/fat in individuals with sulfonylurea-treated KCNJ11 permanent neonatal diabetes. The results showed that post-meal GLP-1 and GIP secretion were similar in cases and controls, suggesting that this process is independent of adenosine triphosphate-sensitive potassium channel.
JOURNAL OF DIABETES INVESTIGATION
(2023)
Review
Pharmacology & Pharmacy
Neil Tanday, Peter R. Flatt, Nigel Irwin
Summary: GLP-1, as an important incretin hormone, has made significant progress in drug development and clinical application, offering a wide range of metabolic benefits. With the clinical approval and continuous evolution of GLP-1 receptor ligands, it is expected that GLP-1 has great potential in treating diseases beyond diabetes and obesity.
BRITISH JOURNAL OF PHARMACOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
John Bucheit, Jessica Ayers, Lauren Pamulapati, Audrieanna Browning, Evan Sisson
Summary: The incretin hormone system is an important target for the treatment of type 2 diabetes. Glucagon-like peptide-1 receptor agonists can lower blood sugar and weight, but have no effect on glucose-dependent insulinotropic polypeptide. Tirzepatide is a novel incretin agent that acts on both GLP-1 and GIP receptors, and has good glucose-lowering and weight loss effects.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
(2022)
Article
Endocrinology & Metabolism
Benedikt A. Aulinger, David A. D'Alessio
Summary: This study compares two different methods to measure the incretin effect and suggests various calculation methods to interpret the results. The study finds that both techniques have similar quantitative results and can be used to measure the incretin effect.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
(2023)
Article
Agriculture, Dairy & Animal Science
L. M. Rings, A. M. Kamr, H. M. Kinsella, L. D. Hostnik, J. M. Swink, T. A. Burns, K. Christie, J. B. David, R. E. Toribio
Summary: This study investigated the enteroinsular axis (EIA) in hospitalized foals by measuring serum insulin and plasma incretin concentrations, revealing differences between hospitalized/septic foals and healthy foals. The study found that certain hormone concentrations were associated with disease severity and outcome in foals, suggesting potential mechanisms contributing to reduced insulin secretion in critically ill foals.
DOMESTIC ANIMAL ENDOCRINOLOGY
(2022)
Review
Endocrinology & Metabolism
Christophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaal
Summary: Glucagon-like peptide-1 receptor agonists and dual GLP-1/glucose-dependent insulinotropic peptide RA tirzepatide have expanded the population of individuals reaching HbA1c and weight targets, showing potential therapeutic benefits. However, further research is needed to determine whether this will lead to improved cardiovascular outcomes and impact treatment guidelines.
DIABETES OBESITY & METABOLISM
(2022)
Article
Urology & Nephrology
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J. Drucker, Yutaka Seino, Yuichiro Yamada
KIDNEY INTERNATIONAL
(2016)
Article
Endocrinology & Metabolism
Yuichiro Yamada, Katsushi Tsukiyama, Takehiro Sato, Tatsunori Shimizu, Hiroki Fujita, Takuma Narita
JOURNAL OF DIABETES INVESTIGATION
(2016)
Article
Endocrinology & Metabolism
Tatsunori Shimizu, Takehiro Sato, Katsushi Tsukiyama, Hiroki Fujita, Shunsuke Kato, Manabu Hoizumi, Hiromitsu Shirasawa, Takuma Narita, Yukihiro Terada, Yutaka Seino, Yuichiro Yamada
Article
Cell Biology
Swayam Prakash Srivastava, Jinpeng Li, Munehiro Kitada, Hiroki Fujita, Yuichiro Yamada, Julie E. Goodwin, Keizo Kanasaki, Daisuke Koya
CELL DEATH & DISEASE
(2018)
Article
Endocrinology & Metabolism
Yuki Fukuoka, Takuma Narita, Hiroki Fujita, Tsukasa Morii, Takehiro Sato, Mariko Harada Sassa, Yuichiro Yamada
JOURNAL OF DIABETES INVESTIGATION
(2019)
Article
Biochemistry & Molecular Biology
Manabu Hoizumi, Takehiro Sato, Tatsunori Shimizu, Shunsuke Kato, Katsushi Tsukiyama, Takuma Narita, Hiroki Fujita, Tsukasa Morii, Mariko Harada Sassa, Yutaka Seino, Yuichiro Yamada
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2019)
Article
Endocrinology & Metabolism
Yumi Suganuma, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Hiroki Fujita, Mariko Harada Sassa, Yuichiro Yamada
JOURNAL OF DIABETES INVESTIGATION
(2020)
Article
Endocrinology & Metabolism
Hitomi Otomo, Mitsuhiko Nara, Shunsuke Kato, Tatsunori Shimizu, Yumi Suganuma, Takehiro Sato, Tsukasa Morii, Yuichiro Yamada, Hiroki Fujita
METABOLISM-CLINICAL AND EXPERIMENTAL
(2020)
Article
Multidisciplinary Sciences
Shunsuke Kato, Takehiro Sato, Hiroki Fujita, Masahiro Kawatani, Yuichiro Yamada
Summary: This study revealed a close relationship between gut microbiota and metabolic disorders, with GLP-1RA potentially affecting them through neural regulation. While an increase in E. coli did not affect the host under normal conditions, bacterial translocation was observed in mice with colitis.
SCIENTIFIC REPORTS
(2021)
Article
Geriatrics & Gerontology
Taiki Sugimoto, Atsushi Araki, Hiroki Fujita, Keiko Honda, Nobuya Inagaki, Takeshi Ishida, Junichi Kato, Minoru Kishi, Kazuki Kobayashi, Kunichi Kouyama, Hisashi Noma, Mitsuru Ohishi, Noriko Satoh-Asahara, Hiroyuki Shimada, Kazuhiro Sugimoto, Susumu Suzuki, Yasushi Takeya, Yoshiaki Tamura, Haruhiko Tokuda, Hiroyuki Umegaki, Hirotaka Watada, Yuichiro Yamada, Takashi Sakurai
Summary: The Japan-Multi-domain Intervention Trial for Prevention of Dementia in Older Adults with Diabetes (J-MIND-Diabetes) is an 18-month study aimed at investigating the effectiveness of multi-domain intervention in preventing cognitive decline in older adults with T2DM. The trial will assess various outcomes including cognitive function, geriatric assessments, metabolic control, and changes in blood and urinary markers over the course of 18 months. This trial will be the first of its kind in Japan to demonstrate the impact of multi-domain intervention on preventing cognitive decline in older adults with T2DM at risk of dementia.
FRONTIERS IN AGING NEUROSCIENCE
(2021)
Editorial Material
Endocrinology & Metabolism
Tatsunori Shimizu, Yuya Takahashi, Hiroki Fujita, Hironori Waki
JOURNAL OF DIABETES INVESTIGATION
(2022)
Article
Endocrinology & Metabolism
Kazuyuki Takahashi, Hiroki Fujita, Naoko Fujita, Yuya Takahashi, Shunsuke Kato, Tatsunori Shimizu, Yumi Suganuma, Takehiro Sato, Hironori Waki, Yuichiro Yamada
Summary: The ingestion of high-RS cooked rice has been shown to reduce insulin and GLP-1 levels in healthy individuals, without affecting GIP levels and gastric emptying.
Article
Endocrinology & Metabolism
Shunsuke Kato, Izumi Otaka, Hanako Toyama, Ryota Kusumi, Kazuyuki Takahashi, Mitsuhiko Nara, Yumi Suganuma, Takehiro Sato, Tsukasa Morii, Hiroki Fujita, Hironori Waki
Summary: HbA1c, commonly used to estimate average blood glucose levels, may not be accurately measured due to factors such as red blood cell lifespan and hemoglobin variants. Two cases of extremely high blood glucose levels were reported, where HbA1c levels were unmeasurable due to increased labile HbA1c levels. This study highlights the importance of considering the effect of extreme hyperglycemia on HbA1c measurements, regardless of the absolute HbA1c level.
DIABETOLOGY INTERNATIONAL
(2022)
Article
Geriatrics & Gerontology
Yuya Takahashi, Hiroki Fujita, Yusuke Seino, Satoko Hattori, Shihomi Hidaka, Tsuyoshi Miyakawa, Atsushi Suzuki, Hironori Waki, Daisuke Yabe, Yutaka Seino, Yuichiro Yamada
Summary: GIP receptor antagonism can suppress IMAT accumulation and promote muscle regeneration, showing potential as a therapeutic approach for sarcopenia.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2023)
Article
Endocrinology & Metabolism
Takehiro Sato, Tatsunori Shimizu, Hiroki Fujita, Yumiko Imai, Daniel J. Drucker, Yutaka Seino, Yuichiro Yamada